Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry

Bente Glintborg, Mikkel Ostergaard, Niels Steen Krogh, Martin Dehn Andersen, Ulrik Tarp, Anne Gitte Loft, Hanne M Lindegaard, Mette Holland-Fischer, Henrik Nordin, Dorte Vendelbo Jensen, Christian Holkmann Olsen, Merete Lund Hetland

Research output: Contribution to journalJournal articleResearchpeer-review

162 Citations (Scopus)

Abstract

To describe the frequency of treatment switching and outcomes among patients with psoriatic arthritis (PsA) who switched tumor necrosis factor α inhibitor (TNFi) agents in routine care.
Original languageEnglish
JournalArthritis & Rheumatism
Volume65
Issue number5
Pages (from-to)1213-23
Number of pages11
ISSN0004-3591
DOIs
Publication statusPublished - 2013

Keywords

  • Adult
  • Antirheumatic Agents
  • Arthritis, Psoriatic
  • Cohort Studies
  • Denmark
  • Drug Substitution
  • Female
  • Health Status
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Recovery of Function
  • Registries
  • Remission Induction
  • Survival Rate
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha

Fingerprint

Dive into the research topics of 'Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry'. Together they form a unique fingerprint.

Cite this